The Optimized Lipid‐Modified Prodrug for CNV Treatment
Advanced Materials · 2025
DOI: 10.1002/adma.202419263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Xinying Lv und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, S…. Hauptthemen laut MEDLINE: Prodrugs, Choroidal Neovascularization, Lipids, Angiogenesis Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Collaborative Innovation Center of Suzhou Nano Science and Technology.
Abstract (Originalsprache)
Choroidal neovascularization (CNV) is a prevalent cause of vision impairment. The primary treatment for CNV involves intravitreal injections of anti‐vascular endothelial growth factor antibodies. Nevertheless, this approach still faces numerous limitations like poor patient compliance, high therapy expenditure and lack of response in some individuals. Herein, a series of anti‐neovascularization prodrugs, SU5402 (SU), modified with lipids of varying chain lengths (C12, C16, C20, C24, C28) is synthesized (SU‐C12, SU‐C16, SU‐C20, SU‐C24, SU‐C28). 1% polyvinyl alcohol (PVA) is used as a stabilizer to create nanoformulations of five prodrugs named SU‐C12 NPs, SU‐C16 NPs, SU‐C20 NPs, SU‐C24 NPs, SU‐C28 NPs. Among these, SU‐C20 NPs significantly prolong the retention of bioactive drug in the eye for up to 70 d. Moreover, SU‐C20 NPs demonstrate superior tissue permeability via enhanced cellular endocytosis and exocytosis. With its prolonged retention and improved penetration, SU‐C20 NPs reduce the fluorescence intensity of fundus leakage by 42.5% and the fluorescence area by 51.5% in CNV mice after four weeks, effectively inhibiting the progression of CNV. Altogether, small molecule drug SU is innovatively modified to improve its effectiveness for treating fundus neovascular diseases, proposing an alternative therapy for wet age‐related macular degeneration (wAMD).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, 215123, China.
- School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
- School of Materials Science and Engineering, Tongji University, Shanghai, 201804, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
- Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
ORCID-Profile: Qian Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Collaborative Innovation Center of Suzhou Nano Science and Technology
- Suzhou Key Laboratory of Nanotechnology and Biomedicine
- 111 Program from the Ministry of Education of China
- National Key Clinical Specialty Discipline Construction Program of China
Zitieren
APA
Lv, X., Shen, J., Du, X., Yue, B., Zhang, Q., Chang, W., Miao, Y., Ji, Z., Chen, L., Gong, Y., Yang, Y., & Chen, Q. (2025). The Optimized Lipid‐Modified Prodrug for CNV Treatment. Advanced Materials. https://doi.org/10.1002/adma.202419263
Vancouver
Lv X, Shen J, Du X, Yue B, Zhang Q, Chang W, et al. The Optimized Lipid‐Modified Prodrug for CNV Treatment. Advanced Materials. 2025. doi:10.1002/adma.202419263
BibTeX
@article{Lv2025,
author = {Lv, Xinying and Shen, Jingjing and Du, Xinwei and Yue, Boyu and Zhang, Qiang and Chang, Wanwan and Miao, Yu and Ji, Zhaoxin and Chen, Linfu and Gong, Yimou and Yang, Yang and Chen, Qian},
title = {The Optimized Lipid‐Modified Prodrug for CNV Treatment},
journal = {Advanced Materials},
year = {2025},
doi = {10.1002/adma.202419263}
}
EUVIMED